Melanoma Research

Article	Citations
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma	41
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients	38
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)	36
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma	32
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)	27
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature	23
Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data	22
Low-level laser irradiation potentiates anticancer activity of p-coumaric acid against human malignant melanoma cells	20
Ultraviolet radiation and cutaneous melanoma: a historical perspective	19
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas	17
Impact of COVID-19 on melanoma diagnosis	17
External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?	17
Acquired lipodystrophy associated with immune checkpoint inhibitors	16
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)	14
The molecular profile of mucosal melanoma	14
BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma	14
Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases	13
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	13
A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma	12
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	11
Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade	10
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting	10
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature	10
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	9
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	9

Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study	9
Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma	9
Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies	8
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	8
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	8
Vascular endothelial growth factor/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma	8
Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study	8
Ultraviolet A radiation exposure and melanoma: a review	8
Identification of prognostic mRNAs in metastatic cutaneous melanoma	7
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	7
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	7
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	7
Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec	7
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	7
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	7
Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma	7
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma	7
Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma	6
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target	6
Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma	6
Melanogenesis and autophagy in melanoma	6
Time trends and age–period–cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986–2014	6
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activ	6
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio	6
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database	6
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	6
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	6
ETS1 promoted cell growth, metastasis and epithelial–mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression	6
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	6
The role of osteopontin in the development and metastasis of melanoma	6
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	6
Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event	6
Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort	5
A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas	5
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases	5
Clinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experience	5
Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1	5
Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study	5
Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma	5
Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells	5
A meta-analysis of melanoma risk in industrial workers	5
Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma	5
Risk factors in pediatric melanoma: a retrospective study of 39 cases	5
MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas	5
An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma	5
Very late recurrence of iris melanoma: 45 years after treatment	5
Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells	5
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients	4
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma	4
Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis	4

GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	4
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases	4
Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma	4
BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients	4
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma	4
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	4
Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma	4
Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases	4
Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma	4
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status	4
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients	4
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	4
Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma	4
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	4
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy	4
Seborrheic keratosis-like melanoma: a diagnostic challenge	4
20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas	4
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	4
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	4
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression	4
Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass	4
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	4
PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review	4
MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project	4
Real-world data on melanoma brain metastases and survival outcome	4
Epidemiology of cutaneous melanoma and melanoma in situ: a 10-year nationwide retrospective cohort study in South Korea	4
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	4
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib	4
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	4
Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy	4
Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy	4
Uveal melanoma metastatic at initial diagnosis: a case series	3
Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants	3
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	3
Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma	3
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi	3
Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report	3
Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson	3
The alternatively spliced RECK transcript variant 3 is a predictor of poor survival for melanoma patients being upregulated in aggressive cell lines and modulating MMP gene expression in vitro	3
Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment	3
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1	3
Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells	3
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	3
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	3
Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma	3
Ultrasound findings of proliferative nodule arising in a congenital melanocytic nevus	3
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	3
Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma	3
Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma	3
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	3
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene	3
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma	3
Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival	3
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	3
Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers	3
Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review	3
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	3
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	3
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	3
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	2
The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies	2
Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)	2
BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma	2
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	2
Use of laboratory hematology data in melanoma research: comments on “A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio” Melanoma Res	2
Robotic CyberKnife radiosurgery for small choroidal melanomas	2
Antibody-drug conjugates: an evolving approach for melanoma treatment	2
Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis	2
Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?	2
Talimogene laherparepvec monotherapy for head and neck melanoma patients	2
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	2
Safety and efficacy of electrochemotherapy in a series of patients with nonmetastasized primary or recurrent anorectal malignant melanoma	2
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib	2
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday	2
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma	2
Fertility preservation for patients with melanoma	2
Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report	2
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma	2
Statin use is associated with improved overall survival in patients with melanoma	2
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma	2

Cardiovascular disease and malignant melanoma	2
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab	2
Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors	2
Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3	2
Choroidal melanoma treatment in times of coronavirus disease 2019	2
Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases	2
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and	2
Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature	2
Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis	2
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience	2
The role of MC1R gene variants and phenotypical features in predicting high nevus count	2
Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model	2
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure	2
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	2
Extreme elevation of acute phase reactants and shock secondary to dabrafenib–trametinib	2
Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study	2
Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1)	2
Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors	2
Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma	2
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early acce	2
Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma	2
Treatment of in-transit melanoma metastases using intralesional PV-10	2
Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma	2
Paradox in melanoma	2
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	2
Prognostic significance of tumor budding in melanoma	2
Nivolumab exposure in a hemodialysis patient with metastatic melanoma	2
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review	2
Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy	2
Nevi and Breslow thickness in melanoma: sex differences?	2
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	2